Sphingolipid rheostat as a potential target for Friedreich’s Ataxia
|Oct 19 2021
Pathophysiology of Muscle Dysfunction in Friedreich’s Ataxia
|Oct 19 2021
Testing the efficacy of dietary butyrate in ameliorating ataxic symptoms in Friedreich’s ataxia mouse models
|Jul 19 2021
Assessment of early somatosensory impairment in the KIKO mouse model of Friedreich’s Ataxia
|Jun 19 2021
Three-dimensional mature cardiac microtissues from human induced pluripotent stem cells to explore mitochondrial dynamics, cardiac function and therapeutic options in Friedreich Ataxia
|Apr 19 2021
Hepcidin-Ferroportin axis in Friedreich’s Ataxia
|Mar 19 2021
Metabolic (mal)adaptation of heart and skeletal muscle to frataxin depletion
|Mar 19 2021
Regulation of frataxin expression – implications for Friedreich’s ataxia therapy
|Mar 19 2021
Defining the therapeutic window and threshold for neuronal gene therapy in Friedreich Ataxia
|Feb 19 2021
Constancy of FRDA phenotypes across neuronal types and development
|Feb 19 2021
The pathogenesis of the major neural lesions in Friedreich ataxia: dorsal root ganglion and dentate nucleus